Ozonides forms of artemisinins inhibit cytomegalovirus (CMV) replication in vitro and in vivo

Case ID:
Disclosure Date:
INVENTION NOVELTY: This technology involves the use of a derivative of artemisinin as a new therapy for Cytomegalovirus (CMV) infection.
VALUE PROPOSITION: CMV infection is recognized as a cause of morbidity and mortality, especially in immunocompromised individuals. CMV is also the most common viral infection in solid organ transplant recipients. Several anti-viral drugs such as ganciclovir, valganciclovir, foscarnet, and cidofovir are used for treating CMV infection, but lack efficacy . The malaria drug, artemisinin and its derivatives show anti-viral activity, suggesting that it could be derivitized to become a viable therapeutic. Inventors have shown that a derivative form of artemisinin can reduce viral load in children . This derivative was found to be effective against Schistosoma japonicum , S. mansoni and S. haematobium. Other features include:
  • Increased bioavailability due longer half-life
  • Enhanced efficacy
TECHNICAL DETAILS: Johns Hopkins researcher have discovered that a derivitive  form of artemisinin is more effective anti-CMV compound, compared to artemisinin. Among the six compounds screened, one entitity had the best selectivity and also showed the best toxicity profile in human fibroblast. This derivative was shown to be effective in a mouse CMV model.
ASSOCIATED INVENTORS: Ravit Boger, Jonathan Vennerstrom
PATENT STATUS: Pending Provisional Application
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
OZONIDES FOR TREATING OR PREVENTING VIRUS INFECTIONS PCT: Patent Cooperation Treaty PCT PCT/US2018/032632   5/15/2018     Pending
For Information, Contact:
Vera Sampels
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum